Citius Pharmaceuticals (CTXR) Operating Margin (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly Operating Margin came in at 785.39% in Q2 2026, up 59.33% quarter-over-quarter from 1930.96% in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) Operating Margin (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported Operating Margin for 2 consecutive years, with 785.39% the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Johnson & Johnson	639.77 Bn	619.01 Bn	17.26 Bn	28.21%
2	AbbVie	445.75 Bn	439.18 Bn	12.70 Bn	37.86%
3	Merck	356.51 Bn	349.37 Bn	12.21 Bn	-3.52%
4	Novartis Ag	268.75 Bn	261.06 Bn	11.24 Bn	32.97%
5	Pfizer	156.41 Bn	144.71 Bn	10.94 Bn	28.37%
6	Sanofi	52.11 Bn	44.73 Bn	10.79 Bn	9.03%
7	Revolution Medicines	43.22 Bn	43.22 Bn	-	-
8	Incyte	24.88 Bn	20.34 Bn	1.57 Bn	41.69%
9	United Therapeutics	21.31 Bn	18.65 Bn	683.80 Mn	42.23%
10	Citius Pharmaceuticals	15.47 Mn	15.47 Mn	1.00 Mn	-785.39%

Historic Data

Download Data